Table 7.
Impact of molecular profiles in treatment outcome in prospective randomized trials
Trial (reference) | CR | OR | PFS | OS |
---|---|---|---|---|
CALGB 9712 (70) | None significant | None significant | IgVH, del 11q, del 17p | IgVH, del 11q, del 17p |
ECOG 2997 (71) | None significant | None significant | IgVH (for FC only), del 11q, del 17p | Not stated |
LRF CLL4 (59) | del 11q, del 17p | del 11q, del 17p | IgVH, del 11q, del 17p | Not stated |
PFS indicates progression-free survival.